Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

SHIRE

(SHP)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Shire : Form 8.5 (EPT/RI) - SHIRE PLC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 06:12am EST

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the 'Code')

1. KEY INFORMATION

(a) Name of exempt principal trader:

Morgan Stanley Capital Services LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Shire plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Shire plc

(d) Date dealing undertaken:

06 DECEMBER 2018

(e)Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes - Takeda Pharmaceutical Company Limited

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchases/sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

ADR

PURCHASES

1,541

178.2900 USD

176.0200 USD

ADR

SALES

21,333

178.5700 USD

175.8000 USD

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

ADR

CFD

LONG

1,151

171.5000 USD

ADR

CFD

LONG

500

176.3380 USD

ADR

CFD

LONG

5,000

176.5136 USD

ADR

CFD

LONG

17

178.0800 USD

ADR

CFD

LONG

17

178.0800 USD

ADR

CFD

LONG

10,000

178.2686 USD

ADR

CFD

SHORT

1,151

171.5000 USD

ADR

CFD

SHORT

100

176.0200 USD

ADR

CFD

SHORT

100

176.0200 USD

ADR

CFD

SHORT

100

176.1300 USD

ADR

CFD

SHORT

1,200

177.7958 USD

ADR

CFD

SHORT

1,100

177.9472 USD

5p ordinary

CFD

LONG

2,000

45.8201 GBP

5p ordinary

CFD

LONG

8,000

45.8201 GBP

5p ordinary

CFD

LONG

54

46.0531 GBP

5p ordinary

CFD

LONG

50

46.0616 GBP

5p ordinary

CFD

LONG

1,050

46.1200 GBP

5p ordinary

CFD

LONG

4,000

46.1643 GBP

5p ordinary

CFD

LONG

1,000

46.1643 GBP

5p ordinary

CFD

SHORT

19,370

46.0938 GBP

5p ordinary

CFD

SHORT

8,556

46.2554 GBP

5p ordinary

CFD

SHORT

731

45.8997 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Typee.g. American, European etc.

Expiry date

Option money paid/ received per unit

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

(ii) Exercise

Class of relevant security

Product descriptione.g. call option

Number of securities

Exercise price per unit

N/A

N/A

N/A

N/A

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit (if applicable)

N/A

N/A

N/A

N/A

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state 'none'

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state 'none'

None

Date of disclosure:

07 DECEMBER 2018

Contact name:

Craig Horsley

Telephone number:

+44(141) 245 7736

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

Disclaimer

Shire plc published this content on 07 December 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 07 December 2018 11:11:07 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHIRE
02/18TAKEDA PHARMACEUTICAL : Notice Regarding Issue of Hybrid Bonds to replace Senior..
AQ
02/15SHIRE : Annual results
CO
02/08Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Cli..
AQ
01/18Alder BioPharmaceuticals Appoints Paul Streck, M.D. Chief Medical Officer
AQ
01/18Alder BioPharmaceuticals Appoints Paul Streck, M.D. Chief Medical Officer
AQ
01/14TAKEDA PHARMACEUTICAL : Shire and SAIIDAC announce planned delisting of notes fr..
AQ
01/11SHIRE PLC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/11SHIRE : and SAIIDAC announce planned delisting of notes from the New York Stock ..
AQ
01/10TAKEDA PHARMACEUTICAL : Completes Acquisition of Shire, Becoming a Global, Value..
AQ
01/09TAKEDA PHARMACEUTICAL : completes acquisition of Shire
AQ
More news
Financials ($)
Chart SHIRE
Duration : Period :
Shire Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
Howard Mayer Chief Medical Officer
Matthew Walker Head-Technical Operations
Andreas Eugen Busch Chief Scientific Officer
Amitabh Singh Director
Susan O’Reilly Secretary & Director
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE0.00%0
JOHNSON & JOHNSON5.85%363 785
PFIZER-3.46%249 168
ROCHE HOLDING LTD.13.89%238 335
NOVARTIS8.12%231 565
MERCK AND COMPANY5.71%210 032